Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion. Ranibizumab was developed by Genentech and marketed by them in the United States, and elsewhere by Novartis, under the brand name Lucentis.
This report contains market size and forecasts of Raibizumab Biosimilars in global, including the following market information:
Global Raibizumab Biosimilars Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Raibizumab Biosimilars Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Raibizumab Biosimilars companies in 2021 (%)
The global Raibizumab Biosimilars market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
AMD Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Raibizumab Biosimilars include Roche, Novartis, Genentech, Pfizer, Sartorius, Eli Lilly, Bayer, Amgen and PlantForm, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Raibizumab Biosimilars manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Raibizumab Biosimilars Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Raibizumab Biosimilars Market Segment Percentages, by Type, 2021 (%)
AMD
CNV
DME
Global Raibizumab Biosimilars Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Raibizumab Biosimilars Market Segment Percentages, by Application, 2021 (%)
ARMD
Diabetic Retinopathy
Macular Edema
Global Raibizumab Biosimilars Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Raibizumab Biosimilars Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Raibizumab Biosimilars revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Raibizumab Biosimilars revenues share in global market, 2021 (%)
Key companies Raibizumab Biosimilars sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Raibizumab Biosimilars sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Novartis
Genentech
Pfizer
Sartorius
Eli Lilly
Bayer
Amgen
PlantForm
PharmaPraxis
Samsung Bioepis
Centus
Cadila Pharmaceuticals
Dr Reddy's
Aurobindo Pharma
Biocad
MAbxience
Hetero
Biocon
Kirin Biologics
Mylan
BeiGene
Innovent
Qilu Pharmaceutical
Hengrui Pharmaceuticals
Hisun Pharmaceutical
TOT BIOPHARM
Luye Pharmaceutical
Henlius